Samuel Bristow

• Master of Science
• CEO at DHT.health Limited

Objectives There is a paucity of new evidence/literature on the clinical outcomes, healthcare resource use (HCRU), cost and the quality-of-life (QoL) impact on those with von Willebrand Disease (VWD). The PIVOT-VWD study aims to collect patient generated health data to quantify the impact, voice and outcomes of VWD in the UK. Specifically, in relat...

In collaboration with Lived Experience Experts (Patients & Caregivers), we investigated what research had been conducted to understand the burden, quality of life (QoL) and economic cost impact on those with Glanzmann's Thrombasthenia (GT) an ultra-rare inherited bleeding disorder.

The National Institute for Health and Clinical Excellence (NICE) Early Value Assessment (EVA) for digital health and medical technologies was introduced to provide a rapid assessment based upon clinical effectiveness and value for money whilst providing guidance on what further evidence is required. This review aimed to quantify the recommendations...

Objectives Glanzmann thrombasthenia (GT) is a rare inherited platelet disorder caused by quantitative or qualitative defects in integrins αIIb and β3 expressed on the platelet surface. Variants in ITGA2B and ITGB3 render GPIIb/IIIa receptor for fibrinogen absent or non-functional on platelets, hindering platelet aggregation. Consequently, the inabi...

Link to poster: https://www.postersessiononline.eu/173580348_eu/congresos/WFH2024/aula/-PO_93_WFH2024.pdf

Modern treatment for haemophilia modifies bleeding phenotype. This study sought to identify the ongoing support needs of those who transition to a milder bleeding phenotype. Quality of life (QoL) and mental health outlook are outcomes important to people living with haemophilia (PWH). The Patient-Reported Outcomes Burdens and Experiences (PROBE) qu...

Introduction: Modern treatment for haemophilia modifies bleeding phenotype. The Learning to Live with Non-severe Haemophilia study sought to identify the ongoing support needs of those who transition to a milder bleeding phenotype. Quality of life (QoL) and mental health outlook (MHO) are outcomes important to people living with haemophilia (PWH)....